Navigation Links
Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
Date:12/20/2007

SAN DIEGO, Dec. 20 /PRNewswire/ -- Conatus Pharmaceuticals Inc. today announced the initiation of a clinical trial with a novel drug candidate for the treatment of liver disease associated with Hepatitis C Virus (HCV) infection in patients who have failed the approved standard of care treatments.

The oral, small molecule drug candidate, CTS-1027, is being studied as a treatment for the inflammatory damage to the liver resulting from infection by HCV. CTS-1027 inhibits the activity of key members of a class of protease enzymes, the matrix metalloproteinases or MMPs. In the liver and in other solid organs, MMPs play an important role in regulating inflammation as well as in maintaining the integrity of the extracellular matrix. CTS-1027 has been shown to be effective in multiple preclinical models of liver disease.

The clinical trial is a double-blind, placebo-controlled, multiple-dose trial lasting for four weeks followed by a voluntary open label period of up to eight additional weeks. The Company expects approximately 100 patients to be enrolled. The clinical trial will be conducted at up to ten medical centers in the U.S. Additional information about the trial can be found at http://www.clinicaltrials.gov (Identifier NCT00570336) or http://clinicaltrials.gov/ct2/show/NCT00570336?term=CTS-1027&rank=1.

"We are excited to initiate this proof of concept trial in HCV patients with CTS-1027," said Steven J. Mento, President and CEO of Conatus. "We believe that CTS-1027 represents a novel approach to treating liver inflammation and look forward to developing this drug candidate to fill an important medical need in HCV-infected patients."

Conatus Pharmaceuticals Inc. is a privately-held specialty pharmaceutical company engaged in the development of innovative human therapeutics to treat
'/>"/>

SOURCE Conatus Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... the Institute for Molecular Medicine Finland (FIMM), University ... a novel "man and machine" decision support system ... was described in PLOS One scientific ... on computer vision algorithms similar to those used ... only the diagnostically most relevant areas. Tablet computers ...
(Date:8/21/2014)... , August 21, 2014 ... ) has announced the addition of the  ... to their offering.       (Logo: ... hormone therapy, is a means of replacing ... by the body. This type of therapy ...
(Date:8/21/2014)... 2014 The College of New Rochelle ... in the Mid-Hudson Region to be designated as a ... applications from qualified “high-technology” businesses that align with the ... to have been selected for the START-UP NY program ... to stimulate economic development in New York by growing ...
(Date:8/21/2014)... YORK , Aug. 21, 2014 ... congratulates Immune Pharmaceuticals Inc., a biotechnology company, on ... Market.  Immune previously traded on OTCQX®, the best ... by OTC Markets Group. Logo - ... Pharmaceuticals on the successful execution of its growth ...
Breaking Biology Technology:A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2
... Sequence Analysis Problem -, - Exhibit to Spotlight ... MISSION VIEJO, Calif., Sept. 26 Supporting ... genomic search,technology, SLIM Search, Inc. announces it is ... Next Generation,Sequencing Conference. The conference will review new ...
... Phil Coggins to Continue as President and CSO, ... Osprey,Pharmaceuticals, Ltd., a privately held biotechnology company developing,first-in-class ... today the appointment of Jack M. Anthony to ... the position of,CEO will continue as President and ...
... September 26 XTL,Biopharmaceuticals Ltd. (NASDAQ: XTLB ... September 24, 2007, the Company received a NASDAQ ... with the minimum,$10 million shareholders, equity requirement for ... forth in Marketplace Rule 4450(a)(3), and that,its ADRs ...
Cached Biology Technology:SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market 2SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market 3SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market 4Osprey Pharmaceuticals Names Jack M. Anthony as CEO 2Osprey Pharmaceuticals Names Jack M. Anthony as CEO 3XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market 2XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market 3
(Date:8/21/2014)... geologist Juliane Mller the Fram Strait is a key region ... this passage between Greenland and Svalbard warm Atlantic water flows ... west side cold Arctic water masses and sea ice push ... A considerable portion of the Atlantic water cools here on ... The circulation of the water caused in this manner drives ...
(Date:8/21/2014)... designed by an international standards process, will be available ... an invited review published in the OnlineFirst version of ... the official journal of the American Society for Parenteral ... reduce the occurrence of misconnection that can be harmful ... are used to join medical devices, components, and accessories ...
(Date:8/21/2014)... in severe abdominal pain, vomiting and systemic inflammation. Every ... with the disease resulting in 1000 deaths. There is ... fluid and nutritional support. , Dr Jason Bruce, ... research, said "The major causes of pancreatitis include bile ... combined with a high fat diet. In fact, the ...
Breaking Biology News(10 mins):Arctic sea ice influenced force of the Gulf Stream 2Arctic sea ice influenced force of the Gulf Stream 3New feeding tube connectors will improve patient safety 2Insulin offers new hope for the treatment of acute pancreatitis 2
... Spanish . Making DNA sequences being passed through ... point that they take on the form of diminutive spaghetti. This ... of the lines of research in which CIC microGUNE is working, ... are shortly to apply for a patent. The technique basically consists ...
... New York / Heidelberg, 6 April 2011 The ... pads of many insects, lizards and spiders give them the ... James Bullock and Walter Federle from the University of Cambridge ... away these adhesive hairs from surfaces are what allows beetles ...
... used to rehabilitate the arms and hands of people who ... the University of Southampton. In a paper to be ... and Technology (IET) Assisted Living Conference, Dr Geoff Merrett, a ... and evaluation of three technologies which could help people who ...
Cached Biology News:DNA stretching -- A new technique being carried out at CIC microGUNE to detect illnesses 2Nature helps to solve a sticky problem 2Scientists develop new technology for stroke rehabilitation 2
Custom LNA Oligonucleotide synthesis ,High quality Custom LNA Oligonucleotides are available for a variety of different specialty applications and innovative products. ,Please inquire for further...
... Plus is a chemiluminescent signal enhancing ... to boost the signal obtained with ... kits. ChemiLucent™ Plus is derived from ... conjugated complex- or chemiluminescent substrate enhancers, ...
... Multi-Disciplinary Team The Schleicher & ... stand-alone work center dedicated to custom ... The facilitys experienced project teams, comprised ... Marketing professionals, work closely with collaborators ...
... microRNA (miRNA) expression profiling service using Paraflo ... highly sensitive and specific direct detection of ... mature miRNA of all species available in ... database (Release 8.2). Our service is comprehensive ...
Biology Products: